Mattia Cremona

Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing

Lisa R. Susswein, Megan L. Marshall, Rachel Nusbaum et al. · Genetics in Medicine · 2015 · 281 citations · Full text

BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation

Britta Stordal, Kirsten M. Timms, Angela M. Farrelly et al. · Molecular Oncology · 2013 · 144 citations · Full text

BCL-2 system analysis identifies high-risk colorectal cancer patients

Andreas U. Lindner, Manuela Salvucci, Clare Morgan et al. · Gut · 2016 · 52 citations

A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib

Naomi Elster, Mattia Cremona, Clare Morgan et al. · Breast Cancer Research and Treatment · 2014 · 48 citations

Radiation Oncology, Breast Oncology, Her2-targeted Therapies Trastuzumab +9

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target

Marta Llauradó Fernández, Amy Dawson, Joshua Hoenisch et al. · Cancer Cell International · 2019 · 44 citations · Full text